Shares of BioXcel Therapeutics collapsed to $0.13 — an 18.9% single-day drop and a staggering 83% plunge from $0.78 just five trading days earlier — after Nasdaq confirmed it will delist BTAI stock following the company's voluntary Chapter 11 bankruptcy filing. BioXcel's Nasdaq Exit and Teva's $57.5 Million Fire Sale: Will Shareholders See a Dime From Bankruptcy?
Shares of BioXcel Therapeutics cratered to $0.13 — an 83% collapse in five days — after Nasdaq confirmed it will delist BTAI following the company's Chapter 11 bankruptcy filing. Trading will be suspended September 8. For a biotech that once traded above $8 in the past year, the speed of this unraveling is breathtaking, and the math for common shareholders is brutal.
• A Cash Crisis Turned Terminal in Weeks. BioXcel's cash crisis reached a head in recent weeks, with the company telling investors it lacked the money to fund operations through the end of August.
The company attributed the filing to a slower-than-anticipated commercial launch of its only approved product, Igalmi — a dissolving film placed under the tongue to treat agitation in patients with schizophrenia or bipolar disorder. In Q1 2026, BioXcel generated just $206,000 in product revenue against a net loss of $12.7 million , a burn rate that left the company fatally dependent on outside capital.
• Teva's Bid Sets a Low Floor for What the Company Is Worth. Teva will acquire substantially all of BioXcel's assets for $57.5 million upfront and up to $67.5 million in milestone payments tied to FDA approval of the at-home version of the drug, with a decision date of November 14, 2026. As the "stalking horse" bidder — meaning Teva sets the minimum price at a court-supervised auction — other buyers can compete to top the bid. But even the maximum $125 million total barely registers against BioXcel's $139.6 million in total liabilities as of March.
• Common Stock Is Almost Certainly Worthless. In bankruptcy, creditors and secured lenders get paid first. With liabilities exceeding any realistic sale price, shareholders sit at the back of a very long line. The filing explicitly aims to "wind down the remaining estates" and liquidate after the asset sale.
With roughly 31.3 million shares outstanding , even the current $0.13 price implies a $4 million market cap — essentially a lottery ticket on an overbid that still wouldn't clear creditor claims.
• The Move to OTC Pink Seals the Liquidity Trap. Once BTAI shifts to the OTC Pink Limited Market — where reporting and disclosure requirements are minimal — trading will become thin and erratic. Any remaining holders face a near-total loss of liquidity, making exit nearly impossible at any meaningful price.
The bottom line: Teva gets a neuroscience drug with real clinical potential at a deep discount. BioXcel shareholders get a lesson in what happens when a single-product biotech runs out of cash before the revenue catches up.